Fundraising Fox

Ochre Bio

YC W20 ↗

London, GB · Founded 2019 · 50 employees · 12 known investors

ochre-bio.com ↗

Ochre Bio develops RNA therapeutics and drug discovery platforms targeting liver disease, combining proprietary human liver datasets with AI-driven causal prediction and human tissue validation models. The company aims to address the global shortage of liver transplants by developing new treatment options for liver fibrosis and cirrhosis.

AI & Machine LearningBiotechHealthtechMedical DevicesGenomicsin /ochre-bio@OchreBioycombinator.com ↗

Founders & leadership· Y Combinator alumni (W20)

QWQuin Wills
Quin WillsinFounder/CSO
CU
Chinwe Ukomadu
ES
Elaine Sullivan
EF
Eliot Forster
JC
Jack Castle

Investors · 12

BackedLondon · $500K – $5M
Beast VenturesHong Kong
CoastCapVienna
Entrepreneur FirstBengaluru · $1M – $7M
ExpaWest Hollywood · $250K – $3M
Hoxton VenturesLondon · $500K – $5M
Lifeforce CapitalChevy Chase · $500K – $5M
Norrsken VCStockholm · $1.1M – $3.2M
Pathway BioventuresChicago
Y CombinatorSan Francisco · $500K
BoxOne VenturesreportedMontréal · $500K
Khosla VenturesreportedMenlo Park · $5K – $50M

Companies House · registry record

View on Companies House ↗
Registered name
OCHRE BIO LTD
Company number
12294967
Status
Active
Company type
Private limited company
Incorporated
4 Nov 2019
Registered office
Hayakawa Building Oxford Science Park, Edmund Halley Road, Oxford, OX4 4GB
Nature of business (SIC)
72110 — Research and experimental development on biotechnology
Accounts
last made up to 31 Dec 2025 · next due 30 Sept 2027
Confirmation statement
last made up to 3 Nov 2025 · next due 17 Nov 2026

Current officers · 1

  • Quin Wills — director, appointed 4 Nov 2019

Source: Companies House public register · retrieved 24 Jul 2026. Contains public sector information licensed under the Open Government Licence v3.0.

In the news